SOLIGENIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was -28.24K shares.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 2.02K shares, a 64.95% decline from fiscal 2020.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 5.76K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2021-12-31 | -28.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 2.02K shares 10-K · filed 2023-03-31 |
| 2020-12-31 | 5.76K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |